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Abstract
Background: The logrank test and the Cox proportional hazards model are routinely applied in the design and
analysis of randomised controlled trials (RCTs) with time-to-event outcomes. Usually, sample size and power
calculations assume proportional hazards (PH) of the treatment effect, i.e. the hazard ratio is constant over the entire
follow-up period. If the PH assumption fails, the power of the logrank/Cox test may be reduced, sometimes severely. It
is, therefore, important to understand how serious this can become in real trials, and for a proven, alternative test to
be available to increase the robustness of the primary test.
Methods: We performed a systematic search to identify relevant articles in four leading medical journals that publish
results of phase 3 clinical trials. Altogether, 50 articles satisfied our inclusion criteria. We digitised published
Kaplan–Meier curves and created approximations to the original times to event or censoring at the individual patient
level. Using the reconstructed data, we tested for non-PH in all 50 trials. We compared the results from the
logrank/Cox test with those from the combined test recently proposed by Royston and Parmar.
Results: The PH assumption was checked and reported only in 28% of the studies. Evidence of non-PH at the 0.10
level was detected in 31% of comparisons. The Cox test of the treatment effect was significant at the 0.05 level in 49%
of comparisons, and the combined test in 55%. In four of five trials with discordant results, the interpretation would
have changed had the combined test been used. The degree of non-PH and the dominance of the p value for the
combined test were strongly associated. Graphical investigation suggested that non-PH was mostly due to a
treatment effect manifesting in an early follow-up and disappearing later.
Conclusions: The evidence for non-PH is checked (and, hence, identified) in only a small minority of RCTs, but
non-PH may be present in a substantial fraction of such trials. In our reanalysis of the reconstructed data from 50 trials,
the combined test outperformed the Cox test overall. The combined test is a promising approach to making trial
design and analysis more robust.
Keywords: Randomised controlled trials, Time-to-event outcome, Logrank test, Cox test, Hazard ratio,
Non-proportional hazards, Combined test, Robustness
Background
The Cox proportional hazards (PH) model is the almost
universally used framework for the analysis of time-to-
event data in randomised controlled trials (RCTs) with a
time-to-event outcome. The primary reason for its popu-
larity is the semi-parametric nature of the model, which
assumes only that the hazard functions of two groups
remain proportional during the entire follow-up period
after randomisation. No parametric form for the baseline
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hazard is postulated. Departure from PH, if anticipated as
a realistic possibility, complicates the design and analysis
of such a trial [1]. Generally, the sample size calculation
assumes that a logrank or equivalent Cox test will be
performed at the analysis stage.
If non-PH is present, the logrank or Cox test may lose
power to detect differences between randomised groups.
From here on, when we refer to the Cox test, we mean the
Cox or logrank test, since they are nearly identical. The
magnitude of the loss of power of the Cox test depends
on the configuration of non-PH, that is, how the hazard
ratio (HR) changes over time [2]. In particular, an early
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treatment effect, in which the HR differs from 1 relatively
early in the follow-up and later approaches or exceeds
1, may severely deplete the power. When estimating the
treatment effect in such cases, we argue that because
the HR varies over time, non-PH destroys the integrity
of a single HR as an adequate and meaningful summary
of the treatment effect [3]. We, therefore, disagree with
authors (e.g. Schemper et al. [4]) who argue for a time-
averaged HR as a useful summary measure in non-PH
situations. For example, the HR may even cross between
<1 and >1.
Recently, Trinquart et al. investigated the prevalence
and implications of non-PH in oncology RCTs reported
in five leading journals during the last 6months of 2014
[5]. They analysed 54 RCTs totalling 33,212 patients. The
selected outcome was time to death in 21/54 trials (39%).
According to the Grambsch–Therneau test [6], there was
evidence of non-PH (p < 0.1) in 24% of the trials. Fur-
ther, they empirically compared the treatment effects as
measured by the HR and by the difference and ratio
of restricted mean survival times (RMSTs) at the most
extreme event time. They concluded in favour of rou-
tine reporting of RMST measures, whether or not the PH
assumption held.
Here, we aim to confirm Trinquart et al.’s findings [5]
on the occurrence of non-PH in a further selection of
real trials. We also assess the performance of the recently
proposed combined test of the treatment effect [2] com-
pared with the Cox test. The combined test may be used to
design the power or sample size and analyse the treatment
effect in trials in which non-PH could occur [7].
Briefly stated, the combined test aims to exploit the
Cox test (which is optimal under PH) and a permutation
test of the maximal difference in RMST between treat-
ment groups across several predefined time points. The
RMST at a given time does not require any distributional
assumption, such as PH. The combined test comprises
the minimum of the Cox and permutation test p values,
corrected for their correlation. The test may detect, for
example, a significant early difference between the sur-
vival curves even when there is non-PH and the HR is not
far from 1.
Our predefined time points for RMST evaluation are
the ten equally spaced times between the 30th and the
100th centiles of the uncensored event times. We chose
the 30th centile because we felt that very early differ-
ences in survival were unlikely to be reliable or of clinical
interest. The 100th centile was chosen because it provides
good power with divergent survival curves, e.g. under PH.
Ten values give reasonable coverage of the curve of p
values for tests of RMST differences. For further insight
into the RMST and RMST difference, we refer the reader
to Fig. 2 of Dehbi et al. [8] and Fig. 3 of Royston and
Parmar [3].
The structure of the article is as follows. In ‘Methods’,
we outline the strategy for selecting eligible trials, the
methodology used to extract data from published Kaplan–
Meier curves and to reconstruct individual-level time-
to-event data, and the Royston–Parmar combined test.
In ‘Results’, we report the outcome of the journal search,
the assessment of non-PH and the application of the Cox
test and the combined test to the reconstructed data. We
end with a Discussion and our Conclusions.
Methods
Data source and selection procedure
We identified eligible phase III RCTs reported in four
leading general medical journals in 2013: theNew England
Journal of Medicine (NEJM), the British Medical Journal
(BMJ), the Lancet and the Journal of the American Med-
ical Association (JAMA). The trials in our study differed
from those in Trinquart et al. [5]’s study by publication
date and by the range of disease areas considered. We
did not limit eligibility to oncology trials. The selection
procedure was as follows.
We included superiority trials where the primary out-
come was subjected to a time-to-event analysis. Our
search string identified 586 potential articles. Two authors
(JKR and BCO) independently reviewed the abstract, full
text and (in some circumstances) the articles’ support-
ing material. Consensus was reached by discussion. We
excluded analyses using pooled data from two or more
trials and reports of secondary, subgroup or follow-up
analyses. Of the 586 articles examined, 50 satisfied the fol-
lowing inclusion criteria: main study publication, phase
III superiority trial, primary outcome was time to event,
and the primary test of the null hypothesis was Cox or
logrank. Five multi-arm trials were included, one 4-arm
trial of macular degeneration, and four 3-arm trials of
HIV, cancer, MRSA and cardiovascular disease.
Data extraction and reconstruction
We extracted information on type of disease, sample size,
median follow-up time, primary endpoint, sample size
and number of events. We ascertained whether a test of
non-PH had been carried out, and if so, we recorded the
type of test. We determined whether the PH assump-
tion was violated, the nature of the violation and which
(if any) methods for handling non-PH were considered.
Finally, we noted whether a logrank or Cox test had been
performed.
As in the procedure followed by Trinquart et al. [5],
we reconstructed individual participant data (IPD) for all
patients in each treatment group from published Kaplan–
Meier curves.We used the DigitizeIt graphical digitisation
package (https://www.digitizeit.de/) to read off the time
and survival probability coordinates from the Kaplan–
Meier curves. Where possible, we extracted the numbers
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of patients at risk and the total number of events. We esti-
mated individual times to event or censoring by using the
community-contributed Stata program ipdfc [9]. The
method is based on an algorithm in R described by Guyot
et al. [10].
Kaplan–Meier curves were digitised and IPD were
reconstructed by an independent person under the super-
vision of BCO. We made informal visual checks of recon-
structed Kaplan–Meier curves compared with those in
the original publication, with satisfactory results. In an
informal assessment, we found good agreement between
the published estimates of the HR and its 95% confidence
interval and those from the data produced by ipdfc.
Combined test of the treatment effect
Under PH, the Cox test has optimal power. The motiva-
tion for the combined test is to capitalise on the strength
of the Cox test when PH is (nearly) satisfied and to pro-
vide insurance (extra power) for cases in which it is not.
Under some patterns of non-PH, the power of the Cox test
is reduced, even drastically. We aimed to boost the power
under such circumstances by combining the Cox test with
a suitable additional test—hence the name ‘combined test’.
More generally, the standard null hypothesis in trial
design is H0: HR = 1 against the alternative H1: HR = δ.
Usually δ < 1, meaning a reduction (for example) in the
mortality rate due to the research treatment. It may hap-
pen that H0 is not rejected at some predefined level α but
that there are substantial, clinically relevant differences
between the two survival curves. In view of the enormous
costs and effort involved in mounting a phase III RCT,
we would wish to avoid the conclusion that the treatment
effect was non-significant and therefore, that the trial was
negative solely because p > α on a test of the primary out-
come that does not cover a wide enough range of relevant
alternative hypotheses, that is of patterns of non-PH.
The challenge due to the limitations of the PH restric-
tion has been recognised in the literature. Although in no
way new, one approach, the RMST, has gained ground as
a summary measure of a survival function and for com-
paring two survival curves. See, for example, A’Hern [11]
for an argument for its use in oncology trials. RMST is the
mean of a time-to-event distribution truncated at a spe-
cific time point, sometimes denoted by t∗. RMST has a
clear interpretation. For example, with t∗ = 3 yr, an RMST
of 2.5 yr for a group of patients implies that when followed
up for 3 yr, on average patients survive 2.5 yr.
The RMST is easily estimated as the area under the cor-
responding survival curve (e.g. a Kaplan–Meier curve) up
to t∗. Unlike the HR, which is dependent on the model,
the treatment effect may be quantified by the difference in
RMST values at t∗, which requires no modelling assump-
tion. Once t∗ has been selected, significance testing of the
difference in RMST between groups is straightforward.
A potential weakness with such a use of RMST is the
choice of t∗. In a clinical trial paradigm, for a single test
of RMST difference to be regarded as valid, t∗ must be
prespecified at the design stage. Under PH, a choice of
t∗ relatively late during the follow-up may confer power
comparable to that of the Cox test [12], but better choices
of t∗ may considerably increase the power under various
patterns of non-PH. To accommodate this feature, Roys-
ton and Parmar [2] suggested testing the RMST difference
at several prespecified values of t∗ during the follow-up,
taking the smallest p value as the basis of a test. They pro-
vided a method based on a permutation test to correct the
resulting p value, which is obviously too small. Lastly they
took the smaller of the corrected p value and that from the
Cox test to give a putative p value, again requiring correc-
tion for multiple testing. The final result was p(CT), the
p value for the combined test, which has approximately
the correct distribution under the global null hypothesis
of equal survival curves, H0: S0(t) = S1(t). Details of the
approach are given in [2]. An implementation of the com-
bined test in Stata is described by Royston [13]. Power and
sample size calculations for the combined test have been
implemented for Stata users by Royston [7].
Results
Characteristics of eligible articles
The selected articles cover a wide spectrum of disease
research. Most studies (68%) came from the NEJM, with
only one eligible article from the BMJ (Fig. 1a). Figure 1b
describes the types of primary outcome. Composite out-
comes, commonly used for cardiovascular disease, were
the most frequent. Research areas were grouped into five
broad categories: cardiovascular, cancer, HIV, intensive
care unit and other. Cardiovascular disease (44%) and can-
cer (22%) were the two most frequent categories (Fig. 1c).
Figure 1d shows the distribution of median follow-up
times in the eligible articles. In 28% of articles, the median
follow-up time was not reported.
Reported assessment of the PH assumption
In 36/50 studies (72%), the PH assumption was not
assessed (or at least, not reported). For the 14 articles
in which it was assessed, the most frequent method
(50%) was testing the interaction between the (log of)
event time and treatment (Table 1). In five articles, evi-
dence for non-PHwas assessed through scaled Schoenfeld
residuals from a Cox model. In four of the five articles,
graphical methods appear to have been used, with no
formal method of assessment, and in one, a formal test
(Grambsch–Therneau) was applied. In the Grambsch–
Therneau test [6], scaled Schoenfeld residuals are corre-
lated with uncensored event times.
Among the 14 (28%) articles in which an assessment
was carried out, violations of the PH assumption were
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Fig. 1 Frequencies of articles. By a journal, b type of time-to-event outcome, c research area and dmedian follow-up time. BMJ BritishMedical Journal,
C/vasc cardiovascular disease, DFS/RFS disease-free or recurrence-free survival, HIV human immunodeficiency virus, ICU intensive care unit, JAMA
Journal of the AmericanMedical Association, NEJM New England Journal of Medicine, NR not reported, OS overall survival, PFS progression-free survival
reported in 2/14 (14%) studies. In one of the two stud-
ies, a post hoc non-PH analysis was performed. In the
other study, contingent on finding non-PH, as the primary
analysis, the follow-up was truncated after a prespeci-
fied cut-off time before applying the Cox PH model. In
seven articles, the outcome of the PH assessment was not
reported. In no study was there evidence of a prespecified
plan to cope with a potential non-PH treatment effect.
Reanalysis of the 50 trials
We performed Cox and combined tests and the
Grambsch–Therneau test of non-PH on data for 55 pair-
wise comparisons of a research arm with control in the 50
trials. The numbers of patients and events, and the results
for each comparison, derived from the reconstructed IPD,
are summarised as cumulative distributions in Fig. 2.
Table 1 Methods used to assess the PH assumption
Method of checking non-PH No. of studies
Treatment × time interaction (likelihood ratio test) 7
Schoenfeld residuals (graphical assessment) 4
Schoenfeld residuals (Grambsch–Therneau test) 1
Method not reported 2
No check done 36
Total 50
PH proportional hazards
The trial sizes ranged between 119 and 16,492, and the
numbers of events between 18 and 1390. The estimated
HR was <1 in 44/55 comparisons. The Cox test of the
treatment effect was significant at the 0.05 level in 27
comparisons (49%). There is evidence of non-PH at the
0.10 level (0.05) in 17 (13) comparisons. The proportion
of trials with non-PH significant at the 0.10 level (31%) is
slightly higher than the 13/54 (24%) reported by Trinquart
et al. [5].
Comparison of Cox and combined tests
Table 2 compares the performance of the Cox and com-
bined tests at a conventional 0.05 significance level. Of the
five discordant trials reported in Table 2, the Cox test has
p < 0.05 in one comparison (trial 6) whereas the com-
bined test has p < 0.05 in four comparisons (from four
2-arm trials). The four trials in which the combined test
dominates were on cardiovascular medicine (two trials),
dermatology and cancer. The fifth trial in which the Cox
test is better was on gastrointestinal disease.
A detailed comparison of survival curves and other
summary information in the five discordant trials is
shown in Fig. 3 and Table 3. In all except trial 18, the
event rate is low (see Smin in Table 3). There is evi-
dence of non-PH in all four trials in which the combined
test is superior (Table 2), but not in trial 6, where the
Cox test is superior. Note, however, that the combined
test is borderline significant (p(CT) = 0.051) in trial 6,
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Fig. 2 Cumulative distributions of basic data and results from reanalysis of IPD of 55 pairwise treatment comparisons from the 50 trials. Values on
the horizontal axis in (d), (e) and (f) are p values from the respective tests and are presented on logarithmic scales. IPD individual participant data, PH
proportional hazards
so the possible power advantage of the Cox model here
is small.
Figure 4 compares the combined and Cox tests, split
according to whether the Cox or permutation test has the
smaller p value. The p value for the combined test is a
transformation of the smaller of p(Cox) and p(perm), the
p value from the permutation test. Note that p(CT) is
an incomplete beta-function transformation of p(min) =
min(p(Cox), p(perm)) [2]. In effect, p(CT) = f × p(min)
where the factor f lies in (1, 1.5), with f → 1 as p(min) →
1 and f → 1.5 as p(min) → 0.
Table 2 Comparative performance of the Cox and combined
tests
Combined test Cox test with p < 0.05
with p < 0.05 No Yes Total
No 24 1 25
Yes 4 26 30
Total 28 27 55
When p(Cox) < p(perm) (left panel), p(CT) = f ×
p(Cox). Since f lies in (1, 1.5), p(CT) exceeds p(Cox), but
never bymore than 50%. In this case, p(CT) is heavily con-
strained by p(Cox). If the Cox model is the correct choice
(i.e. the PH assumption is true), use of the combined test
instead of the Cox test inflates the p value by <50% and
reduces the power. Royston and Parmar [2] illustrated that
the power of the combined test under PHmay be restored
at the design stage by a modest increase in the sample size,
typically around 7 to 8%.
The right panel of Fig. 4 compares p(CT) with p(Cox)
when p(perm) < p(Cox). In most (19) of the 31 com-
parisons in which p(perm) < p(Cox), the combined test
exhibits an advantage over the Cox test. In this case,
p(CT) is not heavily constrained by p(Cox). p(CT) may
be much smaller than p(Cox) and the combined test
presumably then is the more powerful.
Table 4 shows the distribution of the ratio r =
p(CT)/p(Cox) according to whether there is evidence of
non-PH, the criterion p(GT) < 0.1 used by Trinquart
et al. [5]. When r < 1, the combined test is more
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Fig. 3 Kaplan–Meier curves for five trials with discordant p values from the Cox and combined tests of the treatment effect. For legibility, the vertical
scales have been expanded to accommodate the observed ranges of the survival functions. HR hazard ratio
significant than the Cox test, and vice versa. The two
results with r > 1 and p(GT) ≤ 0.5 are from trial 30
(comparison 2) and trial 49.
When there is evidence of non-PH (17/55 comparisons,
31%), the combined test is more significant in 15/17 (88%)
of them. In contrast, when p(GT) ≥ 0.1 (38/55 com-
parisons, 69%), the Cox test is more significant in 29/38
(76%) of them. Thus, the relative performance of the tests
is associated with the strength of evidence for non-PH, at
least according to p value criteria. As already mentioned,
in such an analysis, the relative performance of the Cox
test is mathematically limited, since r is bounded above by
1.5 but below by 0.
Investigation of time-dependent HRs
It appears that the combined test is more powerful when
there is evidence of non-PH. Here we investigate the
patterns of HR(t), the time-dependent HR in the 17
Table 3 Statistics and tests for the five discordant trials
Trial Patients Events Smin HR Test p values
GT Cox Combined
12 4752 645 0.864 0.911 0.001 0.235 <0.001
18 274 131 0.412 0.725 0.045 0.067 0.026
37 7244 164 0.977 0.828 0.033 0.227 0.012
51 3105 756 0.738 0.995 <0.001 0.946 0.007
6 889 64 0.922 0.579 0.766 0.034 0.051
Smin is the smallest observed value of the Kaplan–Meier survival curve for all patients
GT Grambsch–Therneau test, HR hazard ratio
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Fig. 4 Comparison between combined and Cox test p values in 55 randomised treatment-effect comparisons. Values <0.00001 are truncated to
0.00001. The diagonal line is the line of identity. The vertical and horizontal scales are logarithmic. CT combined test
trials with p(GT) < 0.1. Figure 5 shows estimates of
HR(t), based on two methods of analysis. The thin black
lines are smoothed scaled Schoenfeld residuals from a
Cox model on the treatment covariate, together with
pointwise 95% confidence intervals (shaded). The original
points (not shown) estimate lnHR(t) at the event times.
The thicker green lines are estimates of lnHR(t) derived
from Royston–Parmar survival models [14–16] with the
degrees of freedom chosen to minimise the Bayes infor-
mation criterion. Equal candidate degrees of freedom in
the range 1 to 4 for the baseline and time-dependent treat-
ment effect were used. The horizontal red lines denote
lnHR(t) = 0, i.e. HR(t) = 1.
Table 4 Distribution of p value ratio r across 55 comparisons in
50 randomised trials
Ratio (r) Evidence of non-PH Total
r = p(CT)/p(Cox) No (%) Yes (%)
r ≤ 0.5 2 (15) 11 (85) 13 (100)
0.5 < r ≤ 1.0 7 (64) 4 (36) 11 (100)
r > 1.0 29 (94) 2 (6) 31 (100)
Total 38 (69) 17 (31) 55 (100)
Based on evidence of non-PH of the treatment effect, defined by p(GT) < 0.1 .




The predominant visual impression is that the plotted
lines tend to increase from a negative region (denoting a
lower hazard) to a region with lnHR(t) ≥ 0 (zero treat-
ment effect or a higher hazard in the control arm). The
one exception is comparison 49, which seems to show a
late treatment effect. In confirmation, a time-dependent
Cox model with two periods (t < 40 and t ≥ 40 months)
gives estimated HRs of 0.77 (standard error 0.28) and 0.31
(standard error 0.21), respectively, consistent with a late
effect. However, with a total of only 50 events, this trial is
small.
In general terms, the findings suggest that departures
from PH, at least in the sample of trials we examined,
often exhibit as an early treatment effect. Such trials
are precisely the ones for which we expect the com-
bined test to be more powerful than the Cox test [2].
The interpretation is borne out by the analysis of p val-
ues presented in ‘Comparison of Cox and combined tests’
(Table 2). Furthermore, in comparison 49, p(Cox) =
0.021 and p(CT) = 0.032, consistent with our expecta-
tion that the Cox test is more powerful than the com-
bined test under a late treatment effect [2]. Qualitatively,
however, the results of the two tests lead to the same
conclusion.
Figure 6 presents plots similar in construction to Fig. 5,
but here for the 20/38 comparisons with p(GT) > 0.1 and
closest to 1.0. The values of p(GT) range in row order from
0.998 (comparison 39) to 0.620 (comparison 8). According
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Fig. 5 Time-dependent log hazard ratios (green curves) in the 17 comparisons with some evidence of non-PH. Horizontal lines represent
log HR = 0. See text for further details. HR hazard ratio, PH proportional hazards
to the test, they exhibit the least evidence of departure
from PH in the sample of 55 comparisons.
Subjectively, we see little evidence of an early (or late)
treatment effect. Sometimes, a quadratic type of shape is
seen. Because the Grambsch–Therneau test is based on
a linear correlation between scaled Schoenfeld residuals
and event times, by design it is sensitive to monotonic
relationships between HR(t) and t and has low power
against quadratic alternatives.
Discussion
Our primary aim in this report was to compare the per-
formance of the combined test with that of the Cox test,
which is essentially the same as the logrank test. To do
this, we sought a realistic database of RCTs in the medi-
cal specialities in which many such trials are performed.
Further, we needed IPD.We satisfied the first requirement
through a systematic review that selected relevant arti-
cles published in four key journals in 2013. The second we
achieved by applying a relatively recent technology con-
sisting of digitising Kaplan–Meier curves followed by a
statistical algorithm devised by Guyot et al. [10] to gen-
erate realistic IPD values. We were able to confirm the
finding of Trinquart et al. [5] of unrecognised but poten-
tially important non-PH among survival curves in such
trials.
Overall, our reanalysis of the reconstructed IPD showed
that the combined test indicated a treatment effect signif-
icant at the 0.05 level more often than the Cox test. In ear-
lier simulation work [2], the power of the combined test
was found to be greater when an early treatment effect was
present. This observation was confirmed in the present
study. Graphical analysis of scaled Schoenfeld residuals
(Figs. 5 and 6), a tool used to investigate the relation of the
HR with follow-up time, suggested that an early treatment
effect was often present, even when non-PH was not for-
mally significant according to the Grambsch–Therneau
test.
In defining the combined test, we replaced the standard
null hypothesis of HR = 1 with the more general formula-
tion S0(t) = S1(t), that is, with identical survival functions
in the control and research arms. A plethora of tests of the
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Fig. 6 Time-dependent log hazard ratios in the 20 comparisons with p values from the Grambsch–Therneau test nearest to 1.0
equality of two survival curves has appeared in the litera-
ture. It is beyond the scope of the present article to make
comparisons with other such tests, which remains a topic
for further research.
Conclusions
Using similar technology, we confirmed the finding of
Trinquart and colleagues that the evidence for non-PH is
checked (and hence, identified) in only a small minority
of RCTs, but that non-PH may be present in a substan-
tial fraction. In our reanalysis of the IPD reconstructed
from Kaplan–Meier estimates of survival functions in 50
trials, the combined test outperformed the Cox test over-
all. The combined test is a promising approach to making
trial design and analysis more robust, warranting further
investigation of its properties, strengths and weaknesses.
For example, the performance of the combined test across
a wider range of non-PH cases needs to be explored.
Finally, our study and that of Trinquart highlight how
important it is for triallists who are designing the sam-
ple size for a time-to-event study to consider carefully
whether the PH assumption is likely to hold in their
research context. The same applies whether, for example,
existing literature or clinical expert information is utilised.
If the PH assumption turns out to be correct, use of a com-
bined test will lead to a small loss in power. However, if the
PH assumption is wrong, use of the Cox or logrank sta-
tistical test may result in a substantial loss of power and a
misleading time-averaged HR.
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